Actively Recruiting
Phase 1 Study to Test Safety and Response to Single and Multiple Doses of MT-201 in Healthy Adults Aged 19 to 55
Led by Mirador Therapeutics, Inc. · Updated on 2025-11-04
72
Participants Needed
1
Research Sites
5 weeks
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the safety, tolerability, pharmacokinetics, and immune response of single and multiple doses of MT-201 in healthy adult volunteers. It is a first-in-human, phase 1 clinical trial designed to gather initial data on how MT-201 behaves in the body and its potential effects in a controlled setting. Participants will receive either single or multiple doses of MT-201 or a placebo, administered through intravenous or subcutaneous routes. The study includes randomized assignment to one of the four groups single ascending dose of MT-201, multiple ascending dose of MT-201, single ascending dose of placebo, or multiple ascending dose of placebo. Both dosing strategies will be carefully monitored to assess safety and tolerability. During the study, participants will be closely observed for any adverse events, with safety assessments conducted up to 40 weeks. Researchers will monitor vital signs, laboratory tests, and immune responses to understand MT-201s effects fully. The trial involves healthy volunteers aged between 19 and 55 years, who will be required to provide written consent and comply with study procedures throughout the duration of the trial.
CONDITIONS
Brief Title
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
Research Team
T
Toll-Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
